| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Crohn Disease; Inflammation | Details |
| NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Chongqing Sidemu Biotechnology Technology Co Ltd | Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms | Details | |
| NKG2D CAR-T Cell | Phase 1 Clinical | Hangzhou Cheetah Cell Therapeutics Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Ovarian Neoplasms | Details | |
| anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University) | Phase 1 Clinical | Xinxiang Medical University | Solid tumours | Details | |
| Anti-NKG2D CAR-NK cells therapy (CNK Cell Therapeutics) | Phase 1 Clinical | CNK Cell Therapeutics Co Ltd | Solid tumours | Details | |
| Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics) | Phase 1 Clinical | Hangzhou CNK Therapeutics Co Ltd | Pancreatic Neoplasms; Solid tumours | Details | |
| NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics) | Clinical | Leukemia, Myeloid, Acute; Ovarian Neoplasms | Details | ||
| NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |